{"product_id":"microport-cardioflow-medtech-corp-2160-product-pipeline-analysis-2023-update","title":"MicroPort CardioFlow Medtech Corp (2160) - Product Pipeline Analysis, 2023 Update","description":"\u003cp\u003eSummary\u003cbr\u003e\nMicroPort CardioFlow Medtech Corp (MicroPort), a subsidiary of MicroPort Scientific Corp, discovers, develops and commercializes medical devices for aortic stenosis, mitral regurgitation and other heart diseases. The company offers vita flow, an aortic valve system; alwide, a balloon catheter; and alpass, an introducer set. It is investigating mitral, tricuspid, and surgical valve products, procedural accessories such as balloon catheters, expandable sheaths, embolic protection devices, and catheter sheaths. MicroPort markets its products through a network of distributors across Europe, the Americas and China. The company partnership with 4C Medical Technologies Inc and ValCare Inc to develop medical solutions. MicroPort is headquartered in Shanghai, China.\u003c\/p\u003e\n\n\u003cp\u003eThis report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.\u003c\/p\u003e\n\n\u003cp\u003eThe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.\u003c\/p\u003e\n\n\u003cp\u003eScope:The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developmentsThe report analyzes all pipeline products in development for the company MicroPort CardioFlow Medtech CorpThe report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch dateThe report provides detailed description of products in development, technical specification and functionsThe report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.Reasons to Buy:Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscapeDesign and develop your product development, marketing and sales strategies by understanding the competitor portfolioTo formulate effective Research \u0026amp; Development strategiesDevelop market-entry and market expansion strategiesExploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust returnPlan mergers and acquisitions effectively by identifying key players of the most promising pipelineIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantageDevelop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etcIdentify, understand and capitalize the next high-value products that your competitor would add in its portfolioNote:Some sections may be missing if data is unavailable for the company\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"June, 2023 \/ 32 Pages \/ MCW16245978","offer_id":47662793949490,"sku":null,"price":900.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/microport-cardioflow-medtech-corp-2160-product-pipeline-analysis-2023-update","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}